Anti‐human‐cytomegalovirus immunoglobulin G levels in glioma risk and prognosis

Cancer Medicine

E. Susan Amirian²  Deborah Marquez-Do²  Melissa L. Bondy¹ 

[1] Department of Pediatrics, Baylor College of Medicine, Houston, Texas;Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas

关键词: Brain neoplasms;    glioma;    human cytomegalovirus;    immunoglobulin G;    immunoglobulin M;    risk factors;   

DOI  :  10.1002/cam4.44

来源: Wiley

【 摘 要 】

Abstract

The role of human cytomegalovirus (HCMV) in glioma development and progression remains controversial. The purpose of our study was to assess the potential associations between anti-HCMV antibodies (immunoglobulin G [IgG] and immunoglobulin M [IgM]) and glioma risk and prognosis using data from the Harris County Case–Control Study. Multivariable logistic regression models were utilized to estimate odds ratios and 95% confidence intervals (CI) for the associations between glioma status and antibody levels among glioma cases (n = 362) and cancer-free controls (n = 462). Hazard ratios and 95% CIs were calculated using Cox proportional hazards regression, adjusting for age, race, and sex, to determine if antibody levels were associated with survival over time among cases. Among IgG-positive participants, increasing anti-HCMV IgG levels were associated with decreasing glioma risk (P for trend = 0.0008), and those with the lowest level of anti-HCMV IgG (<10 U/mL) had the highest glioma risk, controlling for age, sex, and race/ethnicity (OR: 2.51, 95% CI: 1.42–4.43). Antibody levels were not associated with survival among glioma cases. Our study contributes new evidence toward the potential importance of the direct and indirect effects of HCMV infection in gliomagenesis.

【 授权许可】

CC BY   
© 2012 The Authors. Cancer Medicine published by Blackwell Publishing Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.